1. Targeted deletion of Wwox reveals a tumor suppressor function
- Author
-
Aqeilan, Rami I., Trapasso, Francesco, Hussain, Sadiq, Costinean, Stefan, Marshall, Dean, Pekarsky, Yuri, Hagan, John P., Zanesi, Nicola, Kaou, Mohamed, Stein, Gary S., Lian, Jane B., and Croce, Carlo M.
- Subjects
Tumor suppressor genes -- Research ,Oxidoreductases -- Structure ,Oxidoreductases -- Research ,Cancer cells -- Research ,Cancer -- Genetic aspects ,Cancer -- Research ,Science and technology - Abstract
The WW domain-containing oxidoreductase (WWOX) spans the second most common fragile site of the human genome, FRA16D, located at 16q23, and its expression is altered in several types of human cancer. We have previously shown that restoration of WWOX expression in cancer cells suppresses tumorigenicity. To investigate WWOX tumor suppressor function in vivo, we generated mice carrying a targeted deletion of the Wwox gene and monitored incidence of tumor formation. Osteosarcomas in juvenile [Wwox.sup.-/-] and lung papillary carcinoma in adult [Wwox.sup.+/-] mice occurred spontaneously. In addition, [Wwox.sup.+/-] mice develop significantly more ethyl nitrosourea-induced lung tumors and lymphomas in comparison to wild-type littermate mice. Intriguingly, these tumors still express Wwox protein, suggesting haploinsuffiency of WWOX itself is cancer predisposing. These results indicate that WWOX is a bona fide tumor suppressor. common fragile site | FHIT | knockout | osteosarcoma | lung cancer
- Published
- 2007